Astrotech Corporation Form 10-K Summary
Business Context and Reporting Period
Astrotech Corporation (Nasdaq: ASTC) filed its Form 10-K for the fiscal year ended June 30, 2026. The company commercializes mass spectrometry and gas chromatography technologies through wholly owned subsidiaries serving security, agriculture, breath analysis, industrial process control, and environmental testing markets.
Key operating units include 1st Detect, AgLAB, BreathTech, Pro-Control, EN-SCAN, and the recently approved Lunar Power and Light initiative. The company employed 28 people at June 30, 2026 and operates as one reportable segment.
Financial Performance and Position
| Metric | FY 2026 | FY 2025 | Change |
|---|---|---|---|
| Revenue | $0.913 million | $1.049 million | Down 13.0% |
| Gross profit | $0.217 million | $0.475 million | Down $0.258 million |
| Gross margin | 23.8% | 45.3% | Down 21.5 percentage points |
| Operating expenses | $14.355 million | $15.209 million | Down $0.854 million |
| Loss from operations | $14.138 million | $14.734 million | Improved $0.596 million |
| Net loss | $14.427 million | $13.850 million | Worsened $0.577 million |
| Net loss per share | $8.49 | $8.32 | Worsened $0.17 |
| Net cash used in operating activities | $13.453 million | $12.952 million | Use increased $0.501 million |
Revenue consisted of approximately $610 thousand of product revenue, $205 thousand of grant revenue, and $97 thousand of service revenue. Product revenue declined primarily because the company sold three TRACER 1000 units and one Labrador handheld gas chromatograph in FY 2026, compared with eight TRACER 1000 units in FY 2025. Revenue was concentrated among three customers, which generated approximately 29%, 24%, and 22% of total revenue.
At June 30, 2026, the company had $8.387 million of cash and cash equivalents, $2.947 million of short-term investments, approximately $13.7 million of net working capital, and $20.507 million of total assets. Total liabilities were $4.335 million, consisting primarily of operating and finance lease liabilities and current operating liabilities. The filing does not disclose material conventional debt; lease obligations totaled approximately $2.705 million.
Stockholders’ equity declined to $16.172 million from $22.100 million, principally because of the annual net loss, partially offset by approximately $6.687 million of net ATM proceeds, stock-option exercises, stock-based compensation, and unrealized investment gains.
Material Changes Versus the Prior Comparable Period
- Revenue decreased 13.0%, while cost of revenue increased 21.3%, reducing gross margin from 45.3% to 23.8%.
- SG&A increased 11.4% to $7.871 million, driven by offering-related legal costs, higher labor and severance costs, facility costs, and accounting, compliance, and investor-relations expenses.
- Research and development expense decreased 20.4% to $6.484 million, primarily because of lower consulting, material, equipment, depreciation, and recruiting costs.
- Interest and dividend income fell to $471 thousand from $1.094 million, while realized investment losses increased to $543 thousand from $5 thousand.
- Operating cash use increased to $13.453 million. Investing activities provided $11.817 million, primarily from sales of short-term investments, and financing activities provided $6.923 million, primarily from the ATM offering.
- The company launched the EN-SCAN Labrador HH-GC commercially and announced new ECAC/EU G1 and wand-swabbing certifications for the TRACER 1000.
- The board authorized management to pursue a potential sale of 1st Detect and approved Lunar Initiatives focused on lunar infrastructure, power, resource development, advanced computing, and semiconductor or quantum manufacturing concepts.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expects current cash and operational resources to fund current plans and obligations for at least the next 12 months, but states that substantial additional capital will be required for longer-term operations, product commercialization, and Lunar Initiatives. The company expects continued operating losses and negative operating cash flows until revenue growth is sufficient to support the business, if that occurs.
The company has an ATM program with remaining availability of approximately $43.4 million at June 30, 2026, subject to market conditions and applicable limitations. By September 23, 2026, it had sold 258,856 shares for gross proceeds of approximately $7.9 million. Additional equity financing could materially dilute existing shareholders.
The Lunar Initiatives are exploratory and have no approved formal business plan, capital budget, binding customer, vendor, strategic-partner, financing, power-purchase, or launch commitments. No lunar commercial operations or related revenue currently exist, and the company states that it lacks the technical expertise and financial resources necessary to fully execute these initiatives. Management expects significant future investment, with no assurance of technical, commercial, or financial viability.
The company submitted a proposal to NASA’s CLPS2 program in June 2026 and planned to submit an Appendix A proposal. Neither submission represents a NASA selection, award, contract, funding commitment, or endorsement.
Other significant risks include continued losses, dependence on additional financing, customer concentration, limited commercial history, international sales and tariff exposure, supply-chain dependence on third-party and single-source suppliers, extensive regulatory requirements, cannabis-related legal and regulatory uncertainty, intellectual-property disputes, cybersecurity threats, Nasdaq listing compliance, and substantial stock-price volatility. The filing states that no cybersecurity incident has materially affected the company and that pending legal matters are not expected to have a material adverse effect.
Warranty liabilities were approximately $199 thousand at June 30, 2026. Contractual lease commitments totaled approximately $2.705 million, including $2.653 million of operating lease obligations. The company had no material off-balance-sheet arrangements.
Most Important Facts for Investors to Verify
- Whether the company can reduce its substantial operating cash burn and achieve meaningful recurring revenue growth.
- The status, pricing, dilution, and remaining capacity of the ATM program and any additional capital raises.
- Whether the proposed sale of 1st Detect is completed, the proceeds received, and the effect on ongoing revenue and technology ownership.
- TRACER 1000 customer adoption, TSA checkpoint testing, qualified-list status, and the sustainability of international demand.
- Commercial traction and margins for EN-SCAN, AgLAB, and Pro-Control products.
- The development status, funding sources, technical milestones, and government-award outcomes for the Lunar Initiatives.
- Customer concentration and the absence of long-term contracts with major customers.
- Potential effects of cannabis regulation, tariffs, export controls, supply constraints, and product or medical-device regulatory requirements.
- The company’s ability to maintain Nasdaq listing compliance and manage potential equity dilution.